Core Viewpoint - Samsung Bioepis Co., Ltd. has announced the launch of two denosumab biosimilars, OBODENCE and XBRYK, which reference Prolia and Xgeva, set to be commercially available in Europe by December 2025 and January 2026 respectively [1] Group 1 - OBODENCE is a 60 mg pre-filled syringe biosimilar, while XBRYK is a 120 mg vial biosimilar [1] - The launch aims to address the significant challenge of osteoporosis treatment in Europe, where there are limited options and affordability issues [1]

INCHEON, Korea--(BUSINESS WIRE)-- #BYOOVIZ--Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis' two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen b. ...

Core Insights - Samsung Bioepis and Phrontline Biopharma have entered into a global collaboration agreement to develop, manufacture, and commercialize two Antibody-Drug Conjugate (ADC) assets [1] - The ADC assets include TJ108, which is a bispecific and dual-payload ADC, and another unnamed asset [1] - Samsung Bioepis will receive an exclusive license from Phrontline for one of the ADC assets [1]